<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;p style="text-align: left"&gt;&lt;strong&gt;Date:&lt;/strong&gt; August 30, 2010 &amp;nbsp; &lt;strong&gt;Time: &lt;/strong&gt;8:30 a.m. &amp;ndash; 12:00 p.m.&lt;/p&gt;&lt;p style="text-align: left"&gt;&lt;strong&gt;Location:&amp;nbsp; &lt;/strong&gt;Gaithersburg Marriott Washingtonian Center 9751 Washingtonian Blvd Gaithersburg, MD 20878&amp;nbsp; (parking is limited)&lt;/p&gt;&lt;p style="text-align: left"&gt;&lt;strong&gt;Webcast&lt;/strong&gt;&lt;/p&gt;&lt;p style="text-align: left"&gt;&lt;a target="_blank" href="[!--$ssExternalLink('UCM224193')--]"&gt;View Webcast of August 30 Meeting&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Agenda&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;On August 30, 2010, the committee will receive a report from the Tobacco Product Constituents Subcommittee and discuss a proposed initial list of harmful or potentially harmful constituents, the rational for inclusion of each constituent, established analytical methods as well as the ancillary methods and normalization standards for the identified constituents.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Meeting Materials&lt;/strong&gt; &amp;nbsp;&lt;/p&gt;&lt;p&gt;Links to meeting materials will be added as they become available.&amp;nbsp; FDA intends to make the complete background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web site after the meeting.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Public Participation Information&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Written submissions may be made to the contact person on or before August 23, 2010.&lt;/li&gt;&lt;li&gt;Oral presentations from the public will be scheduled between approximately 10 a.m. and 11 a.m., August 30, 2010.&amp;nbsp; Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before August 13, 2010.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;Time allotted for each presentation may be limited.&amp;nbsp; If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session.&amp;nbsp; The contact person will notify interested persons regarding their request to speak by August 16, 2010.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Contact Information&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;Cristi Stark Center for Tobacco Products Food and Drug Administration 9200 Corporate Boulevard Rockville, MD 20850&lt;/p&gt;&lt;p sizset="28" sizcache="1"&gt;Phone:&amp;nbsp; 1-877-287-1373 (choose Option 4)&amp;nbsp; FAX:&amp;nbsp; 240-276-3761&amp;nbsp; Email:&amp;nbsp; &lt;a href="mailto:TPSAC@fda.hhs.gov"&gt;TPSAC@fda.hhs.gov&lt;/a&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;FDA Advisory Committee Information Line 1-800-741-8138 (301-443-0572 in the Washington DC area) Code: 8732110002 Please call the Information Line for up-to-date information on this meeting.&lt;/p&gt;&lt;p&gt;A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice.&amp;nbsp; Therefore, you should always check the agency&amp;rsquo;s Website and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.&lt;/p&gt;&lt;p&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting.&amp;nbsp; If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web site after the meeting.&lt;/p&gt;&lt;p&gt;Persons attending FDA&amp;rsquo;s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.&amp;nbsp; FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs.&amp;nbsp; If you require special accommodations due to a disability, please contact Cristi Stark at (240) 276-3992 at least 7 days in advance of the meeting.&amp;nbsp; FDA is committed to the orderly conduct of its advisory committee meetings.&amp;nbsp;&lt;/p&gt;&lt;p sizset="29" sizcache="1"&gt;Please visit our Web site at &lt;a href="http://www.fda.gov/oc/advisory/default.htm"&gt;http://www.fda.gov/oc/advisory/default.htm&lt;/a&gt; for procedures on public conduct during advisory committee meetings.&lt;/p&gt;&lt;p&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).&lt;/p&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
